Einsteinweg 55
2333 CC
Overview
of the Program
Friday, September 9
|
08:00 – 08:45 |
Registration |
|
08:45 – 09:00 |
Greetings |
|
09:00 – 10:30 |
First Session (Clinical Studies) |
|
10:30 – 11:00 |
Break |
|
11:00 – 12:30 |
Second Session (Political and Social Issues) |
|
12:30 – 14:00 |
Lunch |
|
14:00 – 15:00 |
IACM General Meeting & IACM Award |
|
15:00 – 15:45 |
Review (Multiple Sclerosis & ALS) |
|
15:45 – 16:15 |
Break |
|
16:15 – 17:45 |
Third session (Basic Research) |
|
17:45 |
End |
|
18:00 |
Bus to Kurhaus Scheveningen (Evening dinner) |
Saturday, September 10
|
08:30 – 09:00 |
Registration |
|
09:00 – 10:30 |
First session (Application and
Pharmacokinetics) |
|
10:30 – 11:00 |
Break |
|
11:00 – 12:30 |
Second session (Miscellaneous) |
|
12:30 – 14:00 |
Lunch |
|
14:00 – 15:00 |
Poster session |
|
15:00 – 15:45 |
Review (Gastrointestinal Inflammation) |
|
15:45 – 16:15 |
Break |
|
16:15 – 17:45 |
Third session (Side Effects, Risks and
Problems) |
|
|
End of the meeting |
Detailed Program
Friday, September 9
|
08:00 – 08:45 |
Registration |
|
08:45 – 09:00 |
Greetings |
|
09:00 – 10:30 |
First Session (Clinical Studies) |
|
09:00 – 09:15 |
Philip Robson, Derick Wade, Petra Makela, Heather
House, Cynthia Bateman |
Cannabis-based
medicinal extract (Sativex) produced significant improvements in a subjective
measure of spasticity which were maintained on long term treatment with no
evidence of tolerance |
|
09:15 – 09:30 |
Donald Abrams |
Cannabis in HIV-related
peripheral neuropathy: results of a randomized placebo-controlled trial |
|
09:30 – 09:45 |
F. Markus Leweke, Dagmar Koethe, Christoph W. Gerth,
Brit M. Nolden, Daniela Schreiber, Anita Hänsel, Miriam A. Neatby, Antje
Juelicher, Martin Hellmich, Joachim Klosterkötter |
Cannabidiol as an
antipsychotic. a double-blind, controlled clinical trial on Cannabidiol vs.
Amisulpride in acute schizophrenia. |
|
09:45 – 10:00 |
Andrea
Pelliccia, Gianpaolo Grassi, Angela Romano, Paolo Crocchiolo |
Treatment with CBD in oily
solution of drug-resistant paediatric epilepsies |
|
10:00 – 10:15 |
Jeffrey Y. Hergenrather, Tod H. Mikuriya, David
Bearman |
Clinical improvement and reduction of
immunosuppressive drug therapy in cannabis treated patients with Crohn's
disease |
|
10:15 – 10:30 |
Gernot Ernst,
Claudia Denke, Marcus Reif, Martin Schnelle, Hartmut Hagmeister |
Standardized cannabis extract in the treatment of
postherpetic neuralgia – a randomized, double-blind, placebo-controlled
cross-over study |
|
10:30 – 11:00 |
Break |
|
11:00 – 12:30 |
Second session (Political and Social Issues) |
|
11:00 – 11:15 |
Marco van
de Velde |
Two years
of experience with legal production and distribution of medicinal cannabis in
the Netherlands |
|
11:15 – 11:30 |
Annemarie Janse,
Nancy Breekveldt-Postma, Joelle Erkens, Ron Herings |
Medicinal
cannabis in the Netherlands |
|
11:30 – 11:45 |
Louise Déry |
Canadian Medical Marijuana Research Program: main
purpose and accomplishments |
|
11:45 – 12:00 |
Dolors Capellŕ, Marta Duran, Sergio Abanades |
The therapeutic use of cannabis project in
Catalonia: information, prescription and research |
|
|
Dale Gieringer |
The growth of cannabis medicine in the |
|
|
Mark Gibson |
Canna-Biz Chocolate, production, and despatch to
sufferers of multiple sclerosis |
|
12:30 – 14:00 |
Lunch |
|
14:00 – 15:00 |
IACM General Meeting & IACM Award |
|
15:00 – 15:45 |
Review |
|
|
David Baker |
Potential use of cannabinoids in multiple and
amyotrophic lateral sclerosis |
|
15:45 – 16:15 |
Break |
|
16:15 – 17:45 |
Third session (Basic Research) |
|
16:15 – 16:30 |
Ester Fride, Tatiana Bregman, Oded Edelheit, Israel
Hanukoglu, and Amiram Raz |
Cannabinoids and cystic fibrosis (CF): different
regulation of the endocannabinoid CB receptor system in CF mice |
|
|
Natalya M. Kogan, Manuel Guzman, Ester Priel,
Michael Schlesinger, Gergana Marincheva, Ronen Beeri and Raphael Mechoulam |
Quinone type cannabinoids as anticancer compounds |
|
|
Krisztina Monory, Federico Massa, Heike Blaudzun,
Giovanni Marsicano, Beat Lutz |
The
role of different neuronal populations in the pharmacological actions of
delta-9-tetrahydrocannabinol |
|
|
Dagmar
Koethe, Christoph W. Gerth, Daniela Schreiber, Brit M. Nolden, Sonja Gross,
Antje Juelicher, Joachim Klosterkötter, Andrea Giuffrida, Daniele Piomelli,
F. Markus Leweke |
The
endocannabinoid anandamide in CSF is related to the patterns of cannabis use
in first-episode schizophrenia |
|
|
Philipp-Alexander
Brand, Andrea Paris, Jens Scholz,
Kristina Lueken; Peter Tonner |
Cannabinoids and their interaction with anesthesia
in mice |
|
|
Roger G. Pertwee, Lesley A. Stevenson, Ruth A. Ross,
Martin R. Price, Gemma L. Baillie, Kerrie N. Wease and Adčle Thomas |
The plant cannabinoid,
delta-9-tetrahydrocannabivarin, selectively antagonizes R-(+)-WIN55212, anandamide
and delta-9-tetrahydrocannabinol |
|
17:45 |
End |
|
18:00 |
Bus to Kurhaus Scheveningen (Evening dinner) |
Saturday, September 10
|
08:30 – 09:00 |
Registration |
|
09:00 – 10:30 |
First session (Application and
Pharmacokinetics) |
|
09:00 – 09:15 |
L. Zuurman, C. Roy, A.
Hazekamp, R. Schoemaker, J. den Hartigh, J.C.M.E. Bender, R. Verpoorte, J.L.
Pinquier, A.F. Cohen, J.M.A. van Gerven |
Effect of THC
administration in humans: methodology study for further pharmacodynamic
studies with cannabinoid agonist or antagonist |
|
|
Tjeert Mensinga, Irma de
Vries, Maaike Kruidenier, Wim Scholten, and Jan Meulenbelt |
Pharmacokinetics and
effects of cannabis at higher exposure levels |
|
|
Arno Hazekamp, Renee Ruhaak,
Lineke Zuurman, Joop van Gerven, Rob Verpoorte |
Optimized administration
of THC for clinical use by vaporizing |
|
|
Donald Abrams |
Vaporization
as a smokeless cannabis delivery system: results of a randomized comparative
trial |
|
10:00 – 10:15 |
Thomas Nadulski, Fritz
Pragst, Gordon Weinberg, Patrik Roser, Martin Schnelle, Eva-Maria Fronk and
Andreas Michael Stadelmann |
Randomized, double-blind,
placebo-controlled study about the effects of cannabidiol (CBD) on the
pharmacokinetics of delta-9-tetrahydrocannabinol (THC) after oral application
of THC vs. standardized cannabis extract |
|
|
Floris de Jong, Frederike
Engels, Jaap Verweij, and Ron Mathijssen |
Influence of medicinal cannabis
on the pharmacokinetics of the anti-cancer agents docetaxel and irinotecan |
|
10:30 – 11:00 |
Break |
|
11:00 – 12:30 |
Second session (Miscellaneous) |
|
11:00 – 11:15 |
Richard E. Musty and Jose Andre de Sousa Crippa |
Potential
therapeutic effects of cannabinoids on anxiety, a review |
|
|
Marieke van Haaster |
Facts
and phantasy, cannabis and MS |
|
|
Yosef
Sarne, Bella Tselnicker, Chagi Pick and Ora Keren |
Dissociating
between the neuroprotective and neurotoxic effects of THC (delta-9
tetrahydrocannabinol) |
|
|
Anita
Holdcroft, Caroline Doré, and Susan Tebbs |
Qualitative
measures of mood and sensory responses to cannabis extract (Cannador) in THE
CANPOP Study |
|
|
Christian Giroud, Frank Sporkert, Arno Hazekamp,
Marc Augsburger, Florianne Monnet-Tschudi, Patrice Mangin |
Chromatographic-mass
spectrometry procedures for determination of cannabinoids in blood and brain
tissues. Application to forensic cases and pharmacological studies |
|
12:15 – 12:30 |
Jörg Fachner |
Comparing
topographic EEG brainmapping changes of cannabis induced and sound-trance
induced altered state of consciousness |
|
12:30 – 14:00 |
Lunch |
|
14:00 – 15:00 |
Poster session |
|
15:00 – 15:45 |
Review |
|
|
Vincenzo Di Marzo |
The role of endocannabinoids in gastrointestinal
inflammation |
|
15:45 – 16:15 |
Break |
|
16:15 – 17:45 |
Third session (Side Effects, Risks and
Problems) |
|
16:15 – 16:30 |
John Zajicek |
Lessons learnt
from the CAMS study |
|
|
Aaron B. Ilan, Alan Gevins, Kemi Role, Hector
Vizoso, Donald I. Abrams |
The
cognitive neurophysiological effects of medicinal marijuana in HIV+ patients
with peripheral neuropathy |
|
|
Sergio Abanades |
Cannabis and neuropsychological performance: results
form a 3 year follow-up study |
|
|
Franjo Grotenhermen, Gero Leson, Günter Berghaus,
Olaf Drummer, Hans-Peter Krüger, Marie Longo, Herbert Moskowitz, Bud Perrine,
Jan Ramaekers, Alison Smiley, Rob Tunbridge |
Developing per se laws for driving under the
influence of cannabis (DUIC) |
|
|
Emmanuel S. Onaivi |
An
endocannabinoid hypothesis of substance abuse |
|
|
Ethan B. Russo |
Sativex adverse event profile and comparison with
Marinol and “medical grade cannabis” in clinical studies |
|
17:45 |
End of the
Meeting |
Posters (Poster Session on
Saturday, 14:00 – 15:00)
|
Marta Duran, Eva Montané, Xavi Vidal, Joan-Ramon Laporte,
Dolors Capellŕ |
Cannabinoids
as antispastic agents for multiple sclerosis: a qualitative systematic review |
|
Arno Hazekamp, Rob Verpoorte |
Solubilizing THC in water by cyclodextrins |
|
Jonathon Arnold, Michelle Holland, Nathan Gunasekaran
and John Allen |